Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 10, 2017, Pages

  Cojutti, Piergiorgio ^a,b   Sartor, Assunta ^a   Righi, Elda ^a   Scarparo, Claudio ^a   Bassetti, Matteo ^a,b   Pea, Federico ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Continuous infusion; K. pneumoniae; KPC+; KPC producing Klebsiella pneumoniae; Meropenem; PK PD

Indexed keywords

CARBAPENEMASE; CREATININE; MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; THIENAMYCIN DERIVATIVE;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; AGED; BACTEREMIA; BLOOD; DRUG EFFECT; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA INFECTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CREATININE; DRUG MONITORING; HUMANS; INFUSIONS, INTRAVENOUS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; THIENAMYCINS;

EID: 85029739251     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00794-17     Document Type: Article

References (40)

1. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798. https://doi.org/10.3201/eid1710.110655.
2. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevic AT, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. 2017. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 17:153–163. https://doi.org/10.1016/S1473-3099(16)30257-2.
3. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798–1803. https://doi.org/10.1111/j.1469-0691.2011.03514.x.
4. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55: 943–950. https://doi.org/10.1093/cid/cis588.
5. Lee GC, Burgess DS. 2012. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 11:32. https://doi.org/10.1186/1476-0711-11-32.
6. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108–2113. https://doi.org/10.1128/AAC.06268-11.
7. Hsu AJ, Tamma PD. 2014. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis 58:1439–1448. https://doi.org/10.1093/cid/ciu069.
8. Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. 2016. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother 17:761–781. https://doi.org/10.1517/14656566.2016.1145658.
9. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328. https://doi.org/10.1128/AAC.02166-13.
10. Cohen J. 2013. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother 68: 490–491. https://doi.org/10.1093/jac/dks460.
11. Pea F, Viale P, Cojutti P, Furlanut M. 2012. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/ pharmacodynamics-based approach. Antimicrob Agents Chemother 56: 6343–6348. https://doi.org/10.1128/AAC.01291-12.
12. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, Isgri S. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133–2143. https://doi.org/10.1093/jac/dkv086.
13. Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, Marini V, Arena A, Molin A, Martelli A, Gratarola A, Viscoli C, Pelosi P, Mattioli F. 2017. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence 8:66 –73. https://doi.org/10.1080/21505594.2016 .1213476.
14. Pea F, Della Siega P, Cojutti P, Sartor A, Crapis M, Scarparo C, Bassetti M. 2017. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents 49:255–258. https://doi.org/10.1016/j.ijantimicag.2016.10.018.
15. Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim DS. 2010. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 65:2428–2435. https://doi.org/10.1093/jac/dkq317.
16. Usman M, Frey OR, Hempel G. 2017. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. Eur J Clin Pharmacol 73:333–342. https://doi.org/10.1007/s00228-016-2172-4.
17. Binder L, Schworer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, Oellerich M, Walson PD. 2013. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit 35:63–70. https://doi.org/10.1097/FTD.0b013e31827d496c.
18. Pai MP, Cojutti P, Pea F. 2015. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. Clin Pharmacokinet 54:933–941. https://doi.org/10.1007/s40262-015-0266-2.
19. Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A. 2016. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol 72:839–848. https://doi.org/10.1007/s00228-016-2053-x.
20. Mathew SK, Mathew BS, Neely MN, Naik GS, Prabha R, Jacob GG, Subramani K, Fleming DH. 2016. A nonparametric pharmacokinetic approach to determine the optimal dosing regimen for 30-minute and 3-hour meropenem infusions in critically ill patients. Ther Drug Monit 38:593–599. https://doi.org/10.1097/FTD.0000000000000323.
21. Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA. 2016. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. Int J Antimicrob Agents 48:542–546. https://doi.org/10.1016/j.ijantimicag.2016.08.015.
22. Kees MG, Minichmayr IK, Moritz S, Beck S, Wicha SG, Kees F, Kloft C, Steinke T. 2016. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J Clin Pharmacol 56: 307–315. https://doi.org/10.1002/jcph.600.
23. Ho VP, Jenkins SG, Afaneh CI, Turbendian HK, Nicolau DP, Barie PS. 2011. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect (Larchmt) 12:325–327. https://doi.org/10.1089/sur.2010.072.
24. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. 2012. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 56:2129–2131. https://doi.org/10.1128/AAC.06389-11.
25. McDonald C, Cotta MO, Little PJ, McWhinney B, Ungerer JP, Lipman J, Roberts JA. 2016. Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients? Minerva Anestesiol 82: 957–965.
26. Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. 10 July 2017. Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother https://doi.org/10.1093/jac/dkx209.
27. Li C, Du X, Kuti JL, Nicolau DP. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730. https://doi.org/10.1128/AAC .00294-06.
28. Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J. 2016. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 194:681–691.
29. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, Kuti JL. 2010. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 48:2402–2406. https://doi.org/10.1128/JCM.00267-10.
30. Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ. 2011. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 49:1795–1798. https://doi.org/10.1128/JCM.02534-10.
31. Fattouh R, Tijet N, McGeer A, Poutanen SM, Melano RG, Patel SN. 2015. What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low-prevalence settings? Antimicrob Agents Chemother 60:1556–1559. https://doi.org/10.1128/AAC.02304-15.
32. Oteo J, Ortega A, Bartolome R, Bou G, Conejo C, Fernandez-Martinez M, Gonzalez-Lopez JJ, Martinez-Garcia L, Martinez-Martinez L, Merino M, Miro E, Mora M, Navarro F, Oliver A, Pascual A, Rodriguez-Bano J, Ruiz-Carrascoso G, Ruiz-Garbajosa P, Zamorano L, Bautista V, Perez-Vazquez M, Campos J, Geih G, Reipi. 2015. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother 59:3406–3412. https://doi.org/10.1128/AAC.00086-15.
33. Findlay J, Hopkins KL, Doumith M, Meunier D, Wiuff C, Hill R, Pike R, Loy R, Mustafa N, Livermore DM, Woodford N. 2016. KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region. J Antimicrob Chemother 71:1199–1206. https://doi.org/10.1093/jac/ dkv476.
34. Findlay J, Hopkins KL, Alvarez-Buylla A, Meunier D, Mustafa N, Hill R, Pike R, McCrae LX, Hawkey PM, Woodford N. 2017. Characterization of carbapenemase-producing Enterobacteriaceae in the West Midlands region of England: 2007–14. J Antimicrob Chemother 72:1054–1062. https://doi.org/10.1093/jac/dkx012.
35. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. https://doi.org/10.1159/000180580.
36. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467– 476. https://doi.org/10.1097/FTD.0b013e31825c4ba6.
37. Dupuis A, Pariat C, Courtois P, Couet W, Bouquet S. 2000. Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations. Fundam Clin Pharmacol 14:163–165. https://doi.org/10.1111/j.1472-8206.2000.tb00406.x.
38. Zhang Y, Zhang J, Chen Y, Yu J, Cao G, Wu X, Chen M, Wu J, Zhao X. 2017. Evaluation of meropenem penetration into cerebrospinal fluid in patients with meningitis after neurosurgery. World Neurosurg 98: 525–531. https://doi.org/10.1016/j.wneu.2016.11.040.
39. Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA. 2014. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 69:1416–1423. https://doi.org/10.1093/jac/dkt523.
40. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. 2005. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 55:71–77. https://doi.org/10.1093/jac/dkh511.